Skip to main content

Vertex Pharmaceuticals Inc

VRTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0000875320

In the last 90 days, Vertex Pharmaceuticals Inc insiders filed 0 open-market purchases and 3 sales; 1,763 institutions reported holding it in 13F filings for Q2 2026, worth $119.7B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Vertex Pharmaceuticals Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
3 filings
3 insiders, $2.00M in total
Insiders trading
3
Net value
−$2.00M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Vertex Pharmaceuticals Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Vertex Pharmaceuticals Inc
NameTitleLast reported holdingLast filingFilings, past year
van Grunsven JasperEVP, CP and NPPO8,682Sep 10, 20261
Ambrose KristenSVP & Chief Accounting Officer11,624Sep 1, 20267
Sachs Bruce IDirector39,000Aug 31, 20266
Tatsis OuraniaEVP, Chief Reg. & Quality Off.53,572Jul 23, 20269
Sachdev AmitEVP Chief Patient & Ext Af Off66,512Jul 23, 20267
Garber Alan MDirector7,344Jul 17, 20263
McKechnie DuncanEVP, Chief Commercial Officer11,001Jul 7, 20268
Liu JoyEVP and Chief Legal Officer19,131Jul 6, 20265
Bozic CarmenEVP and CMO15,337Jun 30, 202615
Bunnage Mark E.EVP, Chief Scientific Officer7,284May 19, 20265
Carney LloydDirector6,315May 5, 20262
Lagarde MichelDirector1,132May 5, 20261
Upadhyay SuketuDirector1,558May 5, 20264
Bhatia Sangeeta N.Director4,924May 5, 20262
McKenzie DianaDirector2,378May 5, 20261
Schneider JenniferDirector1,394May 5, 20261
Thornberry NancyDirector2,109May 5, 20261
Kewalramani ReshmaCEO & President98,278Mar 3, 20266
Wagner Charles F JrEVP, CO & FO47,042Feb 26, 20267
Leiden Jeffrey MExecutive Chairman34,797Feb 26, 20265
Biller JonathanEVP and Chief Legal Officer13,659Feb 26, 20267
Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off.18,432Feb 26, 20266
Altshuler DavidEVP, Chief Scientific Officer34,477Jan 26, 20261
Arbuckle Stuart AEVP, COO63,368Jul 2, 20250
Kearney Terrence CDirector6,536May 3, 20240
Sanna BastianoEVP, Cell & Genetic Therapies32,038May 9, 20230
McGlynn Margaret GDirector178May 3, 20230
Lee YuchunDirector1,875May 3, 20230

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 10, 2022 (view filing)Aug 82 daysBhatia Sangeeta N.DirectorSSale−621$293.03−$182.0K−11.8%4.66K after5 lots
Aug 12, 2022 (view filing)Aug 102 daysLiu JoySVP, General CounselSSale−36$300.32−$10.8K−0.3%13.4K after
Aug 12, 2022 (view filing)Aug 102 daysArbuckle Stuart AEVP, COOSSale−180$300.40−$54.1K−0.3%60.9K after2 lots
Aug 17, 2022 (view filing)Aug 152 daysLiu JoySVP, General CounselSSale−3.75K$303.90−$1.14M−28.1%9.61K after6 lots
Aug 17, 2022 (view filing)Aug 152 daysArbuckle Stuart AEVP, COOSSale−22.2K$303.93−$6.74M−32.9%45.3K after6 lots
Aug 17, 2022 (view filing)Aug 152 daysKewalramani ReshmaCEO & PresidentSSale−11.7K$305.06−$3.57M−10.5%99.6K after
Oct 20, 2022 (view filing)Oct 182 daysSanna BastianoEVP, Cell & Genetic TherapiesSSale−1.79K$300.31−$537.9K−4.4%39.2K after2 lots
Oct 26, 2022 (view filing)Oct 242 daysBhatia Sangeeta N.DirectorSSale−621$310.00−$192.5K−13.3%4.04K after
Nov 3, 2022 (view filing)Nov 21 daySanna BastianoEVP, Cell & Genetic TherapiesSSale−320$312.64−$100.0K−0.8%38.1K after7 lots
Nov 9, 2022 (view filing)Nov 72 daysAltshuler DavidEVP, Global Research and CSOSSale−1.30K$303.04−$394.9K−3.5%36.1K after7 lots
Nov 17, 2022 (view filing)Nov 152 daysAltshuler DavidEVP, Global Research and CSOSSale−34$308.61−$10.5K−0.1%36.1K after
Jan 19, 2023 (view filing)Jan 17-182 daysLee YuchunDirectorSSale−4.44K$312.04−$1.39M−70.3%1.88K after2 lots
Jan 25, 2023 (view filing)Jan 23-242 daysLee YuchunDirectorSSale−6.13K$312.46−$1.92M−76.6%1.88K after3 lots
Jan 27, 2023 (view filing)Jan 252 daysKewalramani ReshmaCEO & PresidentSSale−10.0K$315.05−$3.15M−10.0%89.6K after
Jan 27, 2023 (view filing)Jan 25-262 daysLee YuchunDirectorSSale−8.00K$316.15−$2.53M−81.0%1.88K after9 lots
Jan 31, 2023 (view filing)Jan 274 daysLee YuchunDirectorSSale−1.43K$322.03−$460.2K−43.3%1.88K after3 lots
Jan 31, 2023 (view filing)Jan 301 dayCarney LloydDirectorSSale−2.70K$320.52−$865.4K−39.4%4.15K after3 lots
Feb 2, 2023 (view filing)Jan 312 daysSachs Bruce IDirectorSSale−1.20K$325.01−$390.0K−2.8%41.2K after
Feb 2, 2023 (view filing)Jan 312 daysSanna BastianoEVP, Cell & Genetic TherapiesSSale−106$325.00−$34.5K−0.3%38.0K after
Feb 8, 2023 (view filing)Feb 62 daysAltshuler DavidEVP, Global Research and CSOSSale−1.30K$306.00−$399.0K−1.9%68.6K after6 lots
Feb 14, 2023 (view filing)Feb 131 dayAltshuler DavidEVP, Global Research and CSOSSale−4.80K$298.90−$1.43M−8.1%54.4K after4 lots
Feb 14, 2023 (view filing)Feb 131 dayArbuckle Stuart AEVP, COOSSale−4.89K$298.92−$1.46M−5.6%82.0K after4 lots
Feb 14, 2023 (view filing)Feb 131 daySanna BastianoEVP, Cell & Genetic TherapiesSSale−113$300.39−$33.9K−0.2%61.9K after
Feb 14, 2023 (view filing)Feb 131 dayTatsis OuraniaEVP, Chief Reg. & Quality Off.SSale−275$298.99−$82.2K−0.4%65.8K after5 lots
Feb 16, 2023 (view filing)Feb 142 daysAltshuler DavidEVP, Global Research and CSOSSale−6.40K$298.70−$1.91M−11.8%48.0K after6 lots
Feb 16, 2023 (view filing)Feb 142 daysArbuckle Stuart AEVP, COOSSale−6.40K$298.68−$1.91M−7.8%75.6K after6 lots
Feb 16, 2023 (view filing)Feb 142 daysSanna BastianoEVP, Cell & Genetic TherapiesSSale−2.18K$300.39−$655.2K−3.5%59.7K after2 lots
Feb 16, 2023 (view filing)Feb 142 daysTatsis OuraniaEVP, Chief Reg. & Quality Off.SSale−320$298.52−$95.5K−0.5%65.4K after5 lots
Feb 22, 2023 (view filing)Feb 211 dayAltshuler DavidEVP, Global Research and CSOSSale−4.00K$293.77−$1.18M−9.0%40.2K after4 lots
Feb 22, 2023 (view filing)Feb 211 dayArbuckle Stuart AEVP, COOSSale−2.40K$293.75−$705.6K−3.4%68.7K after4 lots
Feb 22, 2023 (view filing)Feb 211 dayTatsis OuraniaEVP, Chief Reg. & Quality Off.SSale−480$293.75−$141.0K−0.8%60.5K after4 lots
Feb 24, 2023 (view filing)Feb 222 daysArbuckle Stuart AEVP, COOSSale−2.40K$294.33−$706.7K−3.5%66.3K after5 lots
Feb 28, 2023 (view filing)Feb 271 dayAltshuler DavidEVP, Global Research and CSOSSale−4.24K$287.51−$1.22M−11.7%32.0K after3 lots
Feb 28, 2023 (view filing)Feb 271 dayAmbrose KristenSVP & Chief Accounting OfficerSSale−1.21K$287.55−$347.1K−14.2%7.30K after3 lots
Feb 28, 2023 (view filing)Feb 271 dayArbuckle Stuart AEVP, COOSSale−5.03K$287.47−$1.45M−8.2%56.6K after3 lots
Feb 28, 2023 (view filing)Feb 271 dayTatsis OuraniaEVP, Chief Reg. & Quality Off.SSale−354$287.48−$101.8K−0.6%56.8K after3 lots
Mar 14, 2023 (view filing)Mar 10-134 daysWagner Charles F JrEVP & Chief Financial OfficerSSale−4.75K$291.98−$1.39M−8.2%53.4K after14 lots
Mar 20, 2023 (view filing)Mar 164 daysSanna BastianoEVP, Cell & Genetic TherapiesSSale−2.75K$300.59−$825.4K−5.3%49.3K after2 lots10b5-1
Mar 21, 2023 (view filing)Mar 174 daysWagner Charles F JrEVP & Chief Financial OfficerSSale−2.00K$296.39−$592.8K−3.7%51.4K after6 lots10b5-1
Mar 28, 2023 (view filing)Mar 244 daysWagner Charles F JrEVP & Chief Financial OfficerSSale−1.77K$305.38−$539.9K−3.4%49.6K after10b5-1
Apr 6, 2023 (view filing)Apr 42 daysSanna BastianoEVP, Cell & Genetic TherapiesSSale−522$315.81−$164.9K−1.1%47.3K after5 lots10b5-1
Apr 14, 2023 (view filing)Apr 122 daysSachs Bruce IDirectorSSale−21.3K$326.73−$6.96M−34.1%41.2K after3 lots10b5-1
Apr 14, 2023 (view filing)Apr 122 daysSanna BastianoEVP, Cell & Genetic TherapiesSSale−7.57K$326.70−$2.47M−16.0%39.7K after3 lots10b5-1
May 1, 2023 (view filing)Apr 274 daysKewalramani ReshmaCEO & PresidentSSale−3.32K$339.08−$1.12M−2.6%126.7K after3 lots10b5-1
May 3, 2023 (view filing)May 21 dayBhatia Sangeeta N.DirectorSSale−580$348.28−$202.0K−11.1%4.63K after5 lots10b5-1
May 4, 2023 (view filing)May 2-32 daysLeiden Jeffrey MExecutive ChairmanSSale−11.0K$349.98−$3.84M−22.7%37.4K after6 lots10b5-1
May 4, 2023 (view filing)May 2-32 daysSanna BastianoEVP, Cell & Genetic TherapiesSSale−4.40K$350.71−$1.54M−11.1%35.3K after5 lots10b5-1
May 9, 2023 (view filing)May 5-84 daysLeiden Jeffrey MExecutive ChairmanSSale−2.00K$349.25−$699.9K−5.4%35.4K after3 lots10b5-1
May 9, 2023 (view filing)May 5-84 daysSanna BastianoEVP, Cell & Genetic TherapiesSSale−3.27K$350.00−$1.15M−9.3%32.0K after2 lots10b5-1
Jun 1, 2023 (view filing)May 302 daysAmbrose KristenSVP & Chief Accounting OfficerSSale−289$329.82−$95.3K−4.1%6.84K after10b5-1